Wen-Shuz Yeow

Dr. Wen-Shuz Yeow is a Research Fellow at the University of Western Australia's Medical School, affiliated with the Australian Centre for RNA Therapeutics in Cancer and the Harry Perkins Institute of Medical Research. Her work in cancer biology and immunology has earned her an h-index of 22 with 2181 citations. She holds a PhD from UWA and focuses on interferon signaling, tumor suppression mechanisms, and RNA-based cancer therapeutics, contributing to global health goals.

Her primary research interests include Cancer Research, Immunology, and Molecular Biology, with specific expertise in Interferon Type I, Malignant Neoplasms, and Programmed Cell Death. She investigates how interferons regulate cancer immunity and how tumor suppressors like retinoblastoma control cancer progression. Her work on RNA therapeutics aims to develop novel treatments for cancer, aligning with sustainable development goals for health.

Analysis of her publication trends from 2010-2012 reveals consistent focus on molecular oncology pathways including NF-κB, cyclin D1, and autophagy in prostate/breast cancer models. Current projects demonstrate translational expansion into blood circulation therapeutics (NHMRC-funded until 2027) and repurposed immunotherapies for mesothelioma, indicating evolution from basic mechanisms to clinical applications.

Dr. Yeow serves as an Investigator on active grants including the NHMRC project on blood circulation innovation and UWA-funded mesothelioma research. Her prior work includes hepatitis C virus response systems development at the Harry Perkins Institute, reflecting a diverse research portfolio spanning cancer biology and infectious disease mechanisms.

Embedded within the Harry Perkins Institute ecosystem, she collaborates across interdisciplinary teams developing RNA therapeutics and molecular diagnostics, with future work focused on advancing cancer immunotherapy platforms through both institutional and NHMRC-supported initiatives.